Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Angiodynamics (ANGO) Payables (2016 - 2025)

Angiodynamics (ANGO) has disclosed Payables for 15 consecutive years, with $35.4 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Payables rose 1.85% year-over-year to $35.4 million, compared with a TTM value of $35.4 million through Nov 2025, up 1.85%, and an annual FY2025 reading of $33.3 million, down 11.81% over the prior year.
  • Payables was $35.4 million for Q4 2025 at Angiodynamics, up from $31.9 million in the prior quarter.
  • Across five years, Payables topped out at $40.4 million in Q2 2023 and bottomed at $17.1 million in Q1 2021.
  • Average Payables over 5 years is $30.3 million, with a median of $31.6 million recorded in 2024.
  • Peak annual rise in Payables hit 65.04% in 2023, while the deepest fall reached 15.21% in 2023.
  • Year by year, Payables stood at $24.2 million in 2021, then soared by 43.39% to $34.7 million in 2022, then rose by 8.54% to $37.6 million in 2023, then dropped by 7.71% to $34.7 million in 2024, then grew by 1.85% to $35.4 million in 2025.
  • Business Quant data shows Payables for ANGO at $35.4 million in Q4 2025, $31.9 million in Q3 2025, and $33.3 million in Q2 2025.